Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Telix Pharmaceuticals Limited
  6. Summary
    TLX   AU000000TLX2

TELIX PHARMACEUTICALS LIMITED

(TLX)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
07/26/2021 07/27/2021 07/28/2021 07/29/2021 07/30/2021 Date
5.25 5.25 5.06 5.34 5.63 Last
236614 378445 273304 217008 420832 Volume
-0.38% 0.00% -3.62% +5.53% +5.43% Change
Estimated financial data (e)
Sales 2021 29,6 M 21,7 M 21,7 M
Net income 2021 -40,0 M -29,4 M -29,4 M
Net cash position 2021 28,4 M 20,8 M 20,8 M
P/E ratio 2021 -45,8x
Yield 2021 -
Sales 2022 79,1 M 58,0 M 58,0 M
Net income 2022 1,52 M 1,12 M 1,12 M
Net cash position 2022 22,7 M 16,7 M 16,7 M
P/E ratio 2022 -1 581x
Yield 2022 -
Capitalization 1 586 M 1 165 M 1 164 M
EV / Sales 2021 52,6x
EV / Sales 2022 19,8x
Nbr of Employees -
Free-Float 62,3%
More Financials
Company
Telix Pharmaceuticals Limited is a clinical-stage biopharmaceutical company. The Company is focused on development and commercialization of diagnostic and therapeutic products based on radiopharmaceuticals, or molecularly-targeted radiation (MTR). MTR is a novel therapeutic approach that selectively delivers radiation to cells that exhibit certain molecular profiles or targets that may be indicative of cancer. The... 
More about the company
Ratings of Telix Pharmaceuticals Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about TELIX PHARMACEUTICALS LIMITED
07/30TELIX PHARMACEUTICALS : Gets Approval for Equipment Decommissioning at Belgian F..
MT
07/20TELIX PHARMACEUTICALS : Recruiting Patients for Phase 3 Study of Renal Cancer Im..
MT
07/19Telix Pharmaceuticals Limited Provides Update on the Progress of the ZIRCON P..
CI
07/11Kyahn Williamson Joins Telix Pharmaceuticals Limited as Senior Vice President..
CI
07/08CHINA GRAND PHARMACEUTICAL AND HEALT : Partner Telix Doses First Patient in Blad..
MT
07/08Telix Pharmaceuticals Limited Successfully Dosed the First Patient in Phase I..
CI
06/23TELIX PHARMACEUTICALS : Doses First Patient in Bladder Cancer Imaging Study
MT
06/22First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
GL
06/22Telix Pharmaceuticals Limited Announces First Patient Dosed in Clinical Study..
CI
06/21TELIX PHARMACEUTICALS : to Conclude Recruitment of Patients for Brain Cancer Dru..
MT
06/20Telix Pharmaceuticals Limited Provides Clinical Trial Update on TLX101 for Gl..
CI
06/17TELIX PHARMACEUTICALS : Enters Late-Cycle Review with US FDA for Prostate Cancer..
MT
06/16Telix Pharmaceuticals Limited Provides Update on FDA New Drug Application Rev..
CI
06/14TELIX PHARMACEUTICALS : and Applied Radiology Launch TelixU Medical Education Pl..
BU
06/11Scott Law Joins Telix as Senior Vice President, Global Manufacturing Operatio..
CI
More news
News in other languages on TELIX PHARMACEUTICALS LIMITED
06/03DGAP-NEWS : Eckert & Ziegler und Telix Pharmaceuticals schließen Vertrag zur gem..
04/21El NOBLE Registry – Una colaboración internacional para el desarrollo d..
01/12TELIX PHARMACEUTICALS : ARTMS y Telix Pharmaceuticals anuncian la producción exi..
01/12TELIX PHARMACEUTICALS : ARTMS und Telix Pharmaceuticals kündigen erfolgreiche Pr..
2020ORIGINAL-RESEARCH : HEIDELBERG PHARMA AG (von EQUITS GmbH): Kaufen
More news
Chart TELIX PHARMACEUTICALS LIMITED
Duration : Period :
Telix Pharmaceuticals Limited Technical Analysis Chart | TLX | AU000000TLX2 | MarketScreener
Technical analysis trends TELIX PHARMACEUTICALS LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 5,63 AUD
Average target price 5,49 AUD
Spread / Average Target -2,58%
EPS Revisions
Managers and Directors
Christian P. Behrenbruch Group CEO, MD & Executive Director
Douglas Cubbin Chief Financial Officer
Harry Kevin McCann Independent Non-Executive Chairman
Colin Hayward Chief Medical Officer
Michael Wheatcroft Chief Scientist
Sector and Competitors
1st jan.Capi. (M$)
TELIX PHARMACEUTICALS LIMITED48.94%1 165
MODERNA, INC.238.47%141 980
LONZA GROUP AG23.98%57 809
IQVIA HOLDINGS INC.38.25%47 462
CELLTRION, INC.-29.39%30 059
SEAGEN INC.-12.42%27 907